Drug class

Respiratory Inhalers Market Report 2023-2033

Retrieved on: 
Tuesday, January 3, 2023
Organization, Drug class, Table, Mouth, NCBI, Dry-powder inhaler, ICS, Mode, Government, Chronic obstructive pulmonary disease, Asthma, Growth, Recession, COVID-19, CDC, Region, Medicare, SAMA, LAMA, Degenerative disease, Perception, Immunity, COPD, Prevalence, Throat, Market, SABA, LABA, Pulmonary hypertension, Spirometry, Data analysis, Pharmaceutical industry, Liquor, Fossil fuel, Marketing, Oil, Fluticasone/salmeterol

NEW YORK, Jan. 3, 2023 /PRNewswire/ -- Forecasts by Product Type (Standard Pressurised Metered-Dose Inhalers, Pressurised Metered-dose Inhalers, Metered-Dose Inhaler with a Spacer, Dry Powder Inhalers, Soft Mist Inhalers, Others), by Drug Class (ICS, SABA+ICS, SABA, LABA, LAMA, ULABA, SABA+SAMA, LABA+LAMA+ICS, SAMA, Others), by Mode of Operation (Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices, Others), by Indication (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

Key Points: 
  • • Where is the respiratory inhalers market heading and how can you ensure you are at the forefront of the market?
  • You need to discover how this will impact the respiratory inhalers market today, and over the next 10 years:
    • Our 354-page report provides 126 tables and 184 charts/graphs exclusively to you.
  • This report tells you TODAY how the respiratory inhalers market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce.
  • • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising respiratory inhalers prices and recent developments.

Actinic Keratosis Treatment Global Market Report 2022: Future Pipeline Medications and Further Use of Combination Therapy Promise Growth Moving Forward - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Health, Pharmaceutical, Marketing, S.A, Growth, Revenue, Diagnosis, ISCC, III, Prevalence, Topical medication, Squamous cell carcinoma, Drug class, Malignancy, USD, Disease, Neck, Therapy, Extremities, Pharmaceutical industry, Coal, Tirbanibulin

The global actinic keratosis treatment market size is anticipated to reach USD 8.93 billion by 2030., expanding at a CAGR of 4.1% from 2022 to 2030.

Key Points: 
  • The global actinic keratosis treatment market size is anticipated to reach USD 8.93 billion by 2030., expanding at a CAGR of 4.1% from 2022 to 2030.
  • The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment.
  • Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.
  • In addition, future pipeline medications and the increased use of combination therapy are key market drivers.

Global OTC Topical Drugs Market Report 2022: Increasing Number of Skin Diseases and the Prevalence of Musculoskeletal Pain Driving Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022
Health, Pharmaceutical, Cream, Online, Skin, Prevalence, Growth, Country, Population, Drug class, Analgesic, Distribution, Pfizer, Antibiotic, Piramal, Novartis, Global, APAC, Research, Astringent, Crowding, Pain management, Investment, Skin condition, Sanofi, MEA, Mometasone, Industry, Personal care, Teva Pharmaceuticals, Market share, Lists of diseases, OTC, Lists of countries and territories, Hospital, Life expectancy, Formulation, COVID-19, USD, Consumer, Eye, Pharmaceutical industry, Medical device, Health insurance, Healthcare, Petroleum jelly, Antipruritic, Bayer, Lotion

According to a research report published in August 2022, the Global OTC Topical drugs market was valued at USD 44.6 billion in the year 2021.

Key Points: 
  • According to a research report published in August 2022, the Global OTC Topical drugs market was valued at USD 44.6 billion in the year 2021.
  • The global OTC Topical Drugs Market is driven by an increasing number of skin diseases and the prevalence of musculoskeletal pain across the globe.
  • The report analyses the OTC Topical Drugs Market By Indication (Skin Disease management, Pain Management, Eye and Ear care, Others)
    The report analyses the OTC Topical Drugs Market by End User (Personal Care, Hospitals and clinics and others).
  • The Global OTC Topical Drugs Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).

Global Osteoporosis Drugs Market Report (2022 to 2027) - Featuring GlaxoSmithKline, Novartis International and Merck & Co Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022
General Health, Health, Pharmaceutical, Physical Therapy, Managed Care, Risk, Calcium, Forecast, Exercise, Fracture, Calcitonin, Investment, Vitamin D, COVID-19, Class, FDA, Research report, Osteoporosis, Bone density, Drug class, Drug development, Therapy, CAGR, Prevalence, Dietary supplement, Pharmaceutical industry, Growth

The global osteoporosis drugs market is projected to reach $16.43 Billion in 2027, from $12.01 Billion in 2021.

Key Points: 
  • The global osteoporosis drugs market is projected to reach $16.43 Billion in 2027, from $12.01 Billion in 2021.
  • Remarkably, as there is no cure for osteoporosis, FDA has approved drugs to prevent, slow, or stop osteoporosis progress.
  • Globally, Osteoporosis Drugs Market is primarily driven by a significant rise in the prevalence of osteoporosis disorder.
  • Moreover, the senior population globally possessing high susceptibility for osteoporosis is further presumed to boost the high demand for Osteoporosis Drugs.

Global Multiple Sclerosis Market Segmentation 2021-2026, By Drug Class, Route of Administration and Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 24, 2022
Health, Pharmaceutical, Online, Government, Growth, GlaxoSmithKline, Pfizer, Multiple sclerosis, Biogen, Market share, COVID-19, Industry, MS, Person, Bristol Myers Squibb, Route of administration, Administration, USD, Interferon, Hospital pharmacy, Drug class, Traction, Patient, Quality of life, Oral, Novartis, Radiology, Distribution, Immune disorder, Pipeline, Online pharmacy, Pharmaceutical industry, Drug, Frankincense, Pet, Global

The Global Multiple Sclerosis Market was estimated at USD 26.01 Billion in the year 2020.

Key Points: 
  • The Global Multiple Sclerosis Market was estimated at USD 26.01 Billion in the year 2020.
  • The introduction of disease-modifying drugs as a treatment option is a key factor that drives the growth of the global multiple sclerosis market.
  • Moreover, the growth of the global multiple sclerosis market is driven by shift in preference toward oral drugs.
  • Global Multiple Sclerosis Market Segmentation - By Drug Class, By route of Administration, By Distribution Channel
    North America Multiple Sclerosis Market: An Analysis (2016-2026)
    Asia Pacific Multiple Sclerosis Market: An Analysis (2016-2026)

Global Pulmonary Drugs Market (2021 to 2027) - Featuring AstraZeneca, Grifols and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022
Health, Pharmaceutical, Growth, Drug class, Market share, Investment, Prevalence, Porter's five forces analysis, Global, Ansoff Matrix, Industry, USD, Geography, Tobacco smoking, Awareness, CAGR, Observation, COVID-19, Government, Pulmonology, Pharmaceutical industry

The Global Pulmonary Drugs Market is estimated to be USD 56.9 Bn in 2021 and is expected to reach USD 69.94 Bn by 2027, growing at a CAGR of 3.5%.

Key Points: 
  • The Global Pulmonary Drugs Market is estimated to be USD 56.9 Bn in 2021 and is expected to reach USD 69.94 Bn by 2027, growing at a CAGR of 3.5%.
  • With the entry of innovative drugs into the markets, there is an increased scope for market growth.
  • The Global Pulmonary Drugs Market is segmented on the basis of Drug Class, Indication, Distribution Channel, and Geography.
  • The report offers a comprehensive evaluation of the Global Pulmonary Drugs Market.

Global Pulmonary Arterial Hypertension (2021 to 2027) - by Drug Class, Route of Administration, Distribution Mode, and Geography - ResearchAndMarkets.com

Retrieved on: 
Friday, January 21, 2022
Pharmaceutical, Health, Cardiology, CAGR, Patient, Government, Drug class, PAH, Hypertensive emergency, Growth, Global, Geography, Route of administration, Private sector, COVID-19, USD, Technology, Prevalence, Distributed mode loudspeaker, Administration, Awareness, Pharmaceutical industry

The "Global Pulmonary Arterial Hypertension (2021-2027) by Drug Class, Route of Administration, Distribution Mode, and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pulmonary Arterial Hypertension (2021-2027) by Drug Class, Route of Administration, Distribution Mode, and Geography, IGR Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Pulmonary Arterial Hypertension Market is estimated to be USD 8.1 Bn in 2021 and is expected to reach USD 11.68 Bn by 2027, growing at a CAGR of 6.2%.
  • Some of the factors that impact the growth of the global pulmonary arterial hypertension market are the change in the lifestyles, rising geriatric population, and the increasing prevalence of pulmonary arterial hypertension (PAH).
  • Technology advancements such as biomarker and new gene therapy for the treatment and advanced oral drugs create an opportunity for the market.

Global $27.73 Bn Analgesics Markets, 2021-2026 by Drug Type, Drug Class, Pain Type, Route of Administration, Distribution Channel, Application, Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 2, 2021
Health, Pharmaceutical, USD, OTC, Policy, Arthritis, Opioid, Awareness, Trauma, GlaxoSmithKline, Government, AbbVie, Pains, Risk, Administration, AstraZeneca, Geography, Aspen Pharmacare, NSAID, Cancer, Chronic pain, Migraine, Application, Market share, FDA, CAGR, Abbott Laboratories, Analgesic, Degenerative disease, Route of administration, Research, Pharmacy, Sexual abuse, Growth, Peripheral neuropathy, GSK, Drug class, Pharmaceutical industry, Dietary supplement

Furthermore, advancements in treatment choices and the availability of well-established healthcare facilities are propelling the analgesics market demand.

Key Points: 
  • Furthermore, advancements in treatment choices and the availability of well-established healthcare facilities are propelling the analgesics market demand.
  • However, uncontrolled opioid prescriptions, drug misuse, and strict regulation and policy by the government restrain the market and create challenges for the global analgesics market growth.
  • Amongst all, the prescription segment is estimated to hold the highest market share during the forecast period.
  • Amongst all, the internal analgesics segment is estimated to hold the highest market share during the forecast period.

Outlook into the Worldwide Anti-Rheumatics Industry to 2026 - Opportunity Analysis and Industry Forecast - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 5, 2020
Health, Pharmaceutical, Health sciences, Pharmacology, Nonsteroidal anti-inflammatory drugs, Drug class, Medicinal chemistry, Pharmacodynamics, Geriatrics, Corticosteroid, Endocrine system

The "Anti-Rheumatics Market by Drug Class, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Type: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-Rheumatics Market by Drug Class, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Type: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
  • The treatment of this medical condition involves the use of various drugs, known as anti-rheumatics.
  • The major factor that boosts the growth of the anti-rheumatics market include surge in geriatric population worldwide.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.

The global anti-rheumatics market is anticipated to record a CAGR of 2.32% during the projected period of 2020-2028

Retrieved on: 
Monday, April 6, 2020
Health sciences, Disease-modifying antirheumatic drug, Drug class, Pharmacology, Pharmaceutical sciences, Corticosteroid, Anti-inflammatory, Rheumatology

The global anti-rheumatics market is anticipated to record a CAGR of 2.32% during the projected period of 2020-2028.

Key Points: 
  • The global anti-rheumatics market is anticipated to record a CAGR of 2.32% during the projected period of 2020-2028.
  • In addition, different types of drugs are used to treat this condition.For example, disease-modifying anti-rheumatics (DMARDs), nonsteroidal anti-inflammatory drugs, corticosteroids, and others.
  • A rapid increase in the geriatric population is one of the significant factors driving the market.
  • Disease-modifying anti-rheumatics drugs category in the drug class segment garnered the largest market share in 2019.